Symptoms and General Pathology

All Conditions

Nausea

Vomiting

Antiemetics

Dermatologic Agents

Gastrointestinal Agents

All Drugs and Chemicals

Anti-Inflammatory Agents

Antineoplastic Agents

Cardiotonic Agents

Ondansetron

Dexamethasone

Cisplatin

Dexamethasone acetate

Metoclopramide

Dopamine

Dopamine Antagonists

Dopamine Agents

Neurotransmitter Agents

ondansetron 8 mg orally twice a day on days 2-5 and dexamethasone 8 mg orally twice a day on days 2-4 plus metoclopramide 20 mg orally four times a day on day 2-5

ondansetron 8 mg orally twice a day on days 2-5 and dexamethasone 8 mg orally twice a day on days 2-4 plus placebo 20 mg oral four times a day on day 2-5

ondansetron 8 mg orally twice a day on days 2-5 and dexamethasone 8 mg orally twice a day on days 2-4 plus metoclopramide 20 mg oral four times a day on day 2-5

metoclopramide

placebo

Suthinee Ithimakin, MD

The objective of this study is to assess the efficacy and tolerability of metoclopramide added to standard antiemetic regimen for prophylaxis of cisplatin-induced emesis.

Ondansetron plus dexamethasone are standard emetic prophylactic agents for highly emetogenic chemotherapy. Metoclopramide is a dopamine antagonist, which may enhance efficacy of ondansetron and dexamethasone.

Ondansetron Plus Dexamethasone With or Without Metoclopramide as Antiemetic Prophylaxis After Receiving Cisplatin

Randomized, Placebo-controlled Trial of Ondansetron Plus Dexamethasone With or Without Metoclopramide as Antiemetic Prophylaxis in Patients Receiving High Dose Cisplatin in Routine Medical Practice

number of patients who experience no emesis and need no rescue treatment in 5-day period

Siriraj Hospital

Mahidol University

Suthinee Ithimakin

ondansetron 8 mg twice a day on days 2-5, dexamethasone 8 mg twice a day on days 2-4 plus placebo 20 mg four times a day on day 2-5

Placebo

Total

Between 18 and 50 years

>= 50 years

Age, Customized

Sex: Female, Male

Thailand

Region of Enrollment

the study had 80 percent power to detect an absolute difference of 20 percent in complete response (70% for metoclopramide group vs 50% for control group)

Number of Patients Who Had Complete Response

Toxicities and Severity of Nausea and Vomiting

Overall Study

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Ondansetron Plus Dexamethasone With or Without Metoclopramide as Antiemetic Prophylaxis After Receiving Cisplatin	NCT01093690	Cancer	metoclopramide placebo	18 Years -	Mahidol University
Ondansetron Plus Dexamethasone With or Without Metoclopramide as Antiemetic Prophylaxis After Receiving Cisplatin	NCT01093690	Cancer	metoclopramide placebo	18 Years -	Mahidol University

Spots Global Cancer Trial Database for chemotherapy induced nausea and vomiting, metoclopramide